Search

Your search keyword '"Frey, Kirk A"' showing total 826 results
Start Over Author "Frey, Kirk A"
826 results on '"Frey, Kirk A"'

12. Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging

Author

Viglianti, Benjamin L, Wong, Ka Kit, Wimer, Stephanie M, Paraeswaran, Aishwarya, Nan, Bin, Ky, Christy, Townsend, Danyelle M, Rubello, Domenico, Frey, Kirk A, and Gross, Milton D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Bioengineering, Biomedical Imaging, Clinical Trials and Supportive Activities, Clinical Research, Liver Disease, Basal Ganglia, Blood Glucose, Brain, Female, Fluorodeoxyglucose F18, Humans, Hyperglycemia, Linear Models, Liver, Male, Middle Aged, Multivariate Analysis, Positron-Emission Tomography, (18)F-FDG biodistribution, Alzheimer’s, PERCIST, PET, Quantitative imaging, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Pharmacology and pharmaceutical sciences
Abstract

PurposeBlood glucose is routinely measured prior to 18F-fluorodeoxyglucose (FDG) administration in positron emission tomography (PET) imaging to identify hyperglycemia that may affect image quality. In this study we explore the effects of blood glucose levels upon semi-quantitative standardized uptake value (SUV) measurements of target organs and tissues of interest and in particular address the relationship of blood glucose to FDG accumulation in the brain and liver.Methods436 FDG PET/CT consecutive studies performed for oncology staging in 229 patients (226 male) at the Ann Arbor Veterans Administration Healthcare System were reviewed. All patients had blood glucose measured (112.4±34.1mg/dL) prior to injection of 466.2±51.8MBq (12.6±1.4mCi) of FDG. SUV measurements of brain, aortic arch blood-pool, liver, and spleen were obtained at 64.5±10.2min' post-injection.ResultsWe found a negative inverse relationship of brain SUV with increasing plasma glucose, levels for both absolute and normalized (either to blood-pool or liver) values. Higher blood glucose levels had a mild effect upon liver and blood-pool SUV. By contrast, spleen SUV was independent of blood glucose, but demonstrated the greatest variability (deviation on linear regression). In contrast to other tissues, liver and spleen SUV normalized to blood-pool SUV were not dependent upon blood glucose levels.ConclusionThe effects of hyperglycemia upon FDG uptake in brain and liver, over a range of blood glucose values generally considered acceptable for clinical PET imaging, may have measurable effects on semi-quantitative image analysis.

Published
2017

14. Extrahepatic 90Y Complication; Gastric Ulcer Secondary to 90Y Therapy for Liver Metastasis Despite Negative Preprocedural Imaging.

Author

Shea, Connor, Lamberg, Hannah, Turk, Sevcan, Sanogo, Mamadou, Turgeon, Danielle, Nojkov, Broko, Frey, Kirk, and Raffel, David

Abstract

Transarterial radioembolization using yttrium-90 (90Y) therapy has become a standard modality of treatment for primary and metastatic liver malignancies due to its high efficacy rate and relatively low risk of adverse effects compared to other forms of locoregional and systemic therapies. Non-target distribution of radio embolic beads and adjacent structure radiation are the two most common adverse effects. However, these are rarely encountered due to thorough imaging and mapping studies prior to 90Y therapy. We present the case of a 66-year-old male who developed a radiation-induced gastric ulcer following 90Y therapy with negative pre-procedural imaging and mapping who was retrospectively found to have an accessory artery from the left hepatic artery to the gastric antrum. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Author

Jackson, Isaac M., Lee, So Jeong, Sowa, Alexandra R., Rodnick, Melissa E., Bruton, Laura, Clark, Mara, Preshlock, Sean, Rothley, Jill, Rogers, Virginia E., Botti, Leslie E., Henderson, Bradford D., Hockley, Brian G., Torres, Jovany, Raffel, David M., Brooks, Allen F., Frey, Kirk A., Kilbourn, Michael R., Koeppe, Robert A., Shao, Xia, and Scott, Peter J. H.

Published
2020
Full Text
View/download PDF

26. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

Author

Salloway, Stephen, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Escovar, Yavir M., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Farrar, Gill, Smith, Adrian P.L., Buckley, Christopher J., Thal, Dietmar Rudolf, Zanette, Michelle, and Curtis, Craig

Published
2017
Full Text
View/download PDF

28. GABA A Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson's Disease.

Author

Bohnen, Nicolaas I., Barr, Jaimie, Vangel, Robert, Roytman, Stiven, Paalanen, Rebecca, Frey, Kirk A., Scott, Peter J. H., and Kanel, Prabesh

Subjects
GABA receptors, PARKINSON'S disease, BINDING sites, BENZODIAZEPINE receptors, MONOAMINE transporters
Abstract

Flumazenil is an allosteric modulator of the γ-aminobutyric acid-A receptor (GABAAR) benzodiazepine binding site that could normalize neuronal signaling and improve motor impairments in Parkinson's disease (PD). Little is known about how regional GABAAR availability affects motor symptoms. We investigated the relationship between regional availability of GABAAR benzodiazepine binding sites and motor impairments in PD. Methods: A total of 11 Patients with PD (males; mean age 69.0 ± 4.6 years; Hoehn and Yahr stages 2–3) underwent [11C]flumazenil GABAAR benzodiazepine binding site and [11C]dihydrotetrabenazine vesicular monoamine transporter type-2 (VMAT2) PET imaging and clinical assessment. Stepwise regression analysis was used to predict regional cerebral correlates of the four cardinal UPDRS motor scores using cortical, striatal, thalamic, and cerebellar flumazenil binding estimates. Thalamic GABAAR availability was selectively associated with axial motor scores (R2 = 0.55, F = 11.0, β = −6.4, p = 0.0009). Multi-ligand analysis demonstrated significant axial motor predictor effects by both thalamic GABAAR availability (R2 = 0.47, β = −5.2, F = 7.2, p = 0.028) and striatal VMAT2 binding (R2 = 0.30, β = −3.9, F = 9.1, p = 0.019; total model: R2 = 0.77, F = 11.9, p = 0.0056). Post hoc analysis demonstrated that thalamic [11C]methyl-4-piperidinyl propionate cholinesterase PET and K1 flow delivery findings were not significant confounders. Findings suggest that reduced thalamic GABAAR availability correlates with worsened axial motor impairments in PD, independent of nigrostriatal degeneration. These findings may augur novel non-dopaminergic approaches to treating axial motor impairments in PD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Diagnostic yield of whole-body 18F-FDG PET/CT in patients with suspected cardiac sarcoidosis.

Author

Saleh, Jamal K., Barkmeier, Daniel, Frey, Kirk A., and Davenport, Matthew S.

Abstract

Background: Whole-body F-18 FDG PET has been included in the 2014 Heart Rhythm Society guidelines for cardiac sarcoidosis evaluation to identify alternate sites of biopsy prior to endomyocardial biopsy. The purpose of this study was to evaluate the diagnostic yield of whole-body F-18 FDG PET/CT. Methods: All adult patients with suspected cardiac sarcoidosis undergoing same-day cardiac F-18 FDG PET/CT and whole-body F-18 FDG PET/CT between 10/1/2016 and 6/14/2021 to assess potential biopsy sites were retrospectively identified. Clinical indications, findings, recommendations, and outcomes were assessed. Results: Eighty-eight patients were included. Extracardiac PET findings suggestive of sarcoidosis were present in 30 patients (34%), 27 of which had thoracic findings (90%). Sarcoidosis was diagnosed in 11% of patients. Only 1% (1/88) was diagnosed by extrathoracic biopsy of a whole-body PET finding. Incidental findings were common (31%), resulting in 11 additional tests or interventions. Recommendations from extrathoracic findings affected treatment in one case: a drainage catheter placement into an unsuspected pelvic abscess. Conclusion: Addition of whole-body F-18 FDG PET/CT to cardiac F-18 FDG PET/CT for the identification of extrathoracic sites of biopsy in patients with suspected cardiac sarcoidosis has marginal diagnostic yield but commonly results in incidental findings that rarely affect patient outcome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Parkinson Dementia: PET Findings

Author

Bohnen, Nicolaas I., Frey, Kirk A., Dierckx, Rudi A.J.O., editor, Otte, Andreas, editor, de Vries, Erik F.J., editor, van Waarde, Aren, editor, and Leenders, Klaus L., editor

Published
2014
Full Text
View/download PDF

39. Fetal Dose from PET and CT in Pregnant Patients

Author

Burton, Christiane Sarah, primary, Frey, Kirk, additional, Fahey, Frederic, additional, Kaminski, Mark S., additional, Brown, Richard K.J., additional, Pohlen, Judith M., additional, and Shulkin, Barry L., additional

Published
2022
Full Text
View/download PDF

42. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial

Author

Kong, Feng-Ming, Ten Haken, Randall K., Schipper, Matthew, Frey, Kirk A., Hayman, James, Gross, Milton, Ramnath, Nithya, Hassan, Khaled A., Matuszak, Martha, Ritter, Timothy, Bi, Nan, Wang, Weili, Orringer, Mark, Cease, Kemp B., Lawrence, Theodore S., and Kalemkerian, Gregory P.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results